Published on 09/12/2025

Understanding COI/COC in Decentralized Manufacturing Models

1. Introduction to Chain-of-Identity and Chain-of-Custody

In the realm of biologics and advanced therapy medicinal products (ATMPs), successful validation practices ensure that product integrity is maintained throughout the manufacturing process. The concepts of Chain-of-Identity (COI) and Chain-of-Custody (COC) are integral to validating decentralized manufacturing models effectively. These concepts not only safeguard against contamination and misuse but also adhere to regulatory expectations such as those set forth by the FDA, EMA, and other regulatory bodies.

Decentralized manufacturing, particularly significant in ATMPs and personalized medicine, poses unique challenges and opportunities regarding viral clearance validation and the implementation of closed and single-use systems. The emphasis on COI and COC management is paramount to ensure that every component of the biopharmaceuticals chain is accounted for, monitored, and secured, thus protecting the patient’s safety and product efficacy.

2. The Importance of Viral Clearance Validation

Viral clearance validation is a critical step in the life cycle of biopharmaceutical products. It ensures that no viral contaminants are present in the end product, protecting public health and complying with stringent regulatory requirements. The validation process often involves spiking studies that evaluate the effectiveness of the manufacturing systems in removing or inactivating viruses.

In a decentralized model where closed systems and single-use systems are deployed, the validation protocols may vary significantly. The key to successful viral clearance validation lies in understanding the specific risks associated with each component of the production process. Factors to consider include:

• System Integrity: Ensuring that the closed systems are leak-proof and maintained under sterile conditions.
• Aseptic Controls as per Annex 1: Adhering to the validated aseptic controls outlined in Annex 1, which provides guidelines for the manufacture of sterile medicinal products.
• Process Parameters: Understanding and validating the critical process parameters (CPPs) that impact potency identity and other critical quality attributes (CQAs).

The validation protocol should, therefore, include defined criteria for both the spiking studies and the performance of the systems used.

3. Implementing COI and COC in Manufacturing Practices

Effective implementation of COI and COC practices within decentralized manufacturing begins with a comprehensive understanding of the process flows and material transfers involved in the production lifecycle. Central to this implementation are systems and processes that assure the integrity and traceability of all components. Here’s a step-by-step guide to facilitate this implementation:

Step 1: Identify Critical Control Points (CCPs)

The first step is identifying the CCPs in the manufacturing process. These are points in the chain where loss of control could compromise product integrity. Key focus areas include:

• Material sourcing and receipt
• Storage conditions, especially for cold-chain products
• Transfer between processes using closed or single-use systems
• Final product testing parameters and storage before distribution

Step 2: Develop a Robust Documentation System

A well-documented system is essential for tracking materials and ensuring that all aspects of COI and COC are maintained throughout the process. This includes:

• Batch records that capture every step of production
• Logs for equipment used in manufacturing
• Audit trails of material movement and handling

Documentation must align with regulatory expectations such as those from EMA and ICH Q5A(R2).

Step 3: Implement Training Programs

It is essential that staff involved in manufacturing are adequately trained on the principles of COI and COC. Regular training sessions should encompass:

• Regulatory requirements and best practices for COI/COC
• The significance of cold storage conditions and monitoring
• Practices for maintaining aseptic technique in both closed and single-use systems

4. Addressing Challenges in Spiking Studies

Spiking studies are pivotal for determining the effectiveness of viral clearance validation strategies. They simulate real-world conditions by introducing a known quantity of viral agents to ascertain the manufacturing process’s ability to eliminate these contaminants. However, challenges often arise during these studies, particularly in decentralized settings:

Challenge 1: Variability in Raw Materials

In decentralized manufacturing, raw materials may come from diverse locations, which can introduce variability. Establishing a consistent quality of materials through strict vendor qualification processes is crucial.

Challenge 2: Techniques for Integrity Testing

Testing the integrity of closed and single-use systems is essential. Techniques must be employed to ensure that the systems can maintain sterility and that spiking studies yield reliable data. These may include:

• Pressure decay testing
• Bubble leak testing

5. Tailoring Process Performance Qualification (PPQ) and Continuous Process Verification (CPV) for ATMPs

As processes evolve, particularly in decentralized settings, PPQ and CPV protocols must be tailored to ensure they meet the unique requirements for ATMPs. Effective tailoring ensures that the critical quality attributes (CQAs) are consistently met throughout the product lifecycle.

Step 1: Establish Risk-Based Approaches

Identifying high-risk areas within the process allows for focused validation efforts. For instance, processes that significantly impact potency identity are prime candidates for enhanced scrutiny.

Step 2: Continuous Monitoring

Continuous monitoring during manufacturing and post-validation ensures any deviations can be addressed immediately. This includes:

• Implementation of real-time data analytics
• Regular reviews of CQAs and CPPs based on performance data

6. Conclusion and Future Directions

In the dynamic landscape of biologics and ATMP manufacturing, the importance of COI and COC cannot be overstated. The evolution towards decentralized manufacturing models aligns with the trends in personalized medicine, where patient-centered approaches are becoming standard. However, industry professionals must adapt to the complexities this brings, particularly in viral clearance validation and implementing closed/single-use systems.

Future regulatory frameworks, potentially governed by evolving standards from organizations such as WHO and the implementation of novel technologies, will continue to shape the principles of COI and COC. Professionals in the pharmaceutical and biotechnological fields must remain vigilant in their adherence to regulatory standards while innovating to improve processes and outcomes.